This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Accelerate oligonucleotide and peptide products from early discovery to late-stage development & commercialization.

Sustainability in peptide and oligonucleotide manufacturing: An interview with Aspen API

Share this article

What does the future of peptide and oligonucleotide manufacturing look like? We chatted to Dirkjan van Zoelen, Manager, Development and Technical Support, Aspen API about the major milestones and trends to date, and how Aspen API is helping advance sustainability in the industry.

He was interviewed by Michael Dunnet for TIDES TV.

Watch the full interview above or here.

Share this article

Upcoming event

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum

14 - 16 Sep 2022, Kyoto, Japan
Industry leaders and service providers share cutting-edge content and company expertise across the Oligonucleotide, Peptide, mRNA and Drug Delivery spectrum
Go to site